This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX
by Zacks Equity Research
Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
by Zacks Equity Research
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Is Labcorp Stock a Good Pick for Your Portfolio Right Now?
by Zacks Equity Research
Investors are increasingly optimistic about LH due to its partnerships and operational discipline.
Should You Retain Hologic Stock in Your Portfolio Now?
by Zacks Equity Research
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.
Competitive Pressure, Macroeconomic Woes Weigh on NEOG Stock
by Zacks Equity Research
NEOG faces intense competition resulting from competitors' development of new technologies, which could affect the marketability and profitability of its products.
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores
by Zacks Equity Research
Myriad Genetics announces the availability of SneakPeek - the first at-home early fetal sex test in Walmart, Walgreens and CVS stores nationwide.
IART Stock to Gain From New Study Findings on DuraSeal Dural Sealant
by Zacks Equity Research
According to a health economic evaluation, Integra's DuraSeal Dural Sealant is revealed to reduce healthcare costs.
Top Analyst Reports for UnitedHealth, Bank of America & SAP
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Bank of America Corporation (BAC) and SAP SE (SAP).
QGEN Collaborates With McGill University Centre: Stock to Gain?
by Zacks Equity Research
QIAGEN joins forces with McGill University Centre for Microbiome Research to generate evidence-based knowledge for medicine and public health.
Expanding Global Market, NuVasive Benefits to Aid GMED Stock
by Zacks Equity Research
Globus Medical is seeing notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.
Alcon Q3 Earnings Top Estimates, Margins Up, Stock Gains in Afterhours
by Zacks Equity Research
ALC's performance is driven by robust demand for the company's innovative products, balanced geographic footprint and strong execution by the team.
Labcorp Adds New Capabilities to Global Trial Connect: Stock to Gain?
by Zacks Equity Research
LH launches new enhancements to Global Trial Connect to streamline site workflow.
Is Quest Diagnostics Stock a Smart Addition to Your Portfolio Now?
by Zacks Equity Research
DGX exhibits strength in its base business. Increasing utilization of the Advanced Diagnostics offering is another positive.
National Vision Q3 Earnings Top Estimates, Revenues Lag, Stock Tumbles
by Zacks Equity Research
EYE's third-quarter 2024 results reflect ongoing strength in Managed Care, with growth in America's Best stores.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
by Zacks Equity Research
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
ZBH Stock to Gain Support From Market Share Gains Amid Macro Issues
by Zacks Equity Research
Zimmer Biomet expects ROSA and Persona Cementless Knee to enhance its robotics and cementless market penetration to 50% to 60% range at a rapid pace.
Haemonetics' Q2 Earnings and Revenues Top, Stock Up, Margins Expand
by Zacks Equity Research
HAE delivers impressive growth in the top and bottom lines in the second quarter of fiscal 2025.
OPK Stock Gains Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Lower revenues from OPKO Health's products and services dampen its overall third-quarter 2024 performance.
AMN Stock Falls Despite Q3 Earnings & Revenues Beat, Margins Contract
by Zacks Equity Research
AMN Healthcare's dismal results in the majority of its segments led to a soft overall third-quarter performance.
PBH Q2 Earnings Match Estimates, Revenues Beat, Shares Rise
by Zacks Equity Research
Prestige Consumer Healthcare's second-quarter sales are impacted by the ongoing supply chain challenges in the Clear Eyes business.
CLOV Stock Declines Despite Q3 Earnings Beat, FY24 View Revised
by Zacks Equity Research
Clover Health's third-quarter 2024 results continue to benefit from the strength of its business model.
Medtronic Stock Trading at a Discount Before Q2 Earnings: Time to Buy?
by Urmimala Biswas
Like its peers, the impact of the present geopolitical situation may have curbed fiscal second-quarter profits for Medtronic.
Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised
by Zacks Equity Research
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
BDX Stock Gains Following Q4 Earnings Beat and Higher Margins
by Zacks Equity Research
BD's overall topline in the fourth quarter of fiscal 2024 benefits from revenue growth in all segments.